Adrenoleukodystrophy Pipeline Insight, 2019

SKU ID : DEL- 13940354

Publishing Date : 01-Sep-2019

No. of pages : 60

PRICE
1250
4000

  • Adrenoleukodystrophy (ALD) (X-linked Adrenoleukodystrophy)
    Overview:
    "Adrenoleukodystrophy (ALD) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adrenoleukodystrophy pipeline landscape is provided which includes the disease overview and Adrenoleukodystrophy treatment guidelines. The assessment part of the report embraces, in depth Adrenoleukodystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adrenoleukodystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
    Adrenoleukodystrophy (ALD) Understanding
    Adrenoleukodystrophy (ALD) is a X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome. The disease is characterized by loss of myelin surrounding nerve cells in the brain and progressive adrenal gland dysfunction. The disease affects mainly males (hemizygotes), but similar to other X-linked disorders, it is increasingly recognized that females (heterozygotes) may be clinically affected as well. There are three basic forms of ALD: neonatal, childhood and adult-onset. The childhood ALD is the classical and the most severe form and usually it leads to total disability or death. It affects only boys because the genetic defect is sex- linked (carried on the X-chromosome). The common symptoms occur in the ages four and ten and include behavioral problems and poor memory, along with symptoms of loss of vision, seizures, difficulty in swallowing, fatigue, increased skin pigmentation and progressive dementia. The neonatal form affects both male and female infants, progresses rapidly and may include symptoms such as mental retardation, facial abnormalities, seizures, retinal degeneration, and poor muscle tone, enlarged liver and adrenal dysfunction.
    Adrenoleukodystrophy (ALD) Pipeline Development Activities
    The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Adrenoleukodystrophy targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Adrenoleukodystrophy pipeline report covers 10+ companies. Some of the key players include Minoryx Therapeutics (Leriglitazone), Ashvattha Therapeutics (OP 101), bluebird bio (Elivaldogene tavalentivec) etc.
    The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
    Adrenoleukodystrophy (ALD) Analytical Perspective by DelveInsight
    • In-depth Adrenoleukodystrophy Commercial Assessment of products
    This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
    • Adrenoleukodystrophy Clinical Assessment of products
    The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
    Scope of the report
    • The Adrenoleukodystrophy report provides an overview of therapeutic pipeline activity for Adrenoleukodystrophy across the complete product development cycle including all clinical and non-clinical stages
    • It comprises of detailed profiles of Adrenoleukodystrophy therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
    • Detailed Adrenoleukodystrophy Research and Development progress and trial details, results wherever available, are also included in the pipeline study
    • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
    • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Adrenoleukodystrophy
    Reasons to Buy
    • Establish a comprehensive understanding of the current pipeline scenario across Adrenoleukodystrophy to formulate effective R&D strategies
    • Assess challenges and opportunities that influence Adrenoleukodystrophy R&D
    • Develop strategic initiatives by understanding the focus areas of leading companies.
    • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
    • Get in detail information of each product with updated information on each project along with key milestones
    • Devise Adrenoleukodystrophy in licensing and out licensing strategies by identifying prospective partners with progressing projects for Adrenoleukodystrophy to enhance and expand business potential and scope
    • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

    Frequently Asked Questions



    This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

    • By product type
    • By End User/Applications
    • By Technology
    • By Region

    The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
    market Reports market Reports